Amubarvimab

Names

[ Name ]:
Amubarvimab

Biological Activity

[Description]:

Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> SARS-CoV

[In Vitro]

Amubarvimab 对野生型 SARS-CoV-2 具有特异性活性，并且与其他冠状病毒无交叉反应[1]。 Amubarvimab 结合两个区域，跨越受体结合基序 (RBM) 中的氨基酸 453-505 和 RBD 核心区域中的氨基酸残基 403-421[1]。

[In Vivo]

Amubarvimab (10-50 mg/kg; i.p.) 与 Romusevimab 联合给药可显着降低 SARS-CoV-2 感染的叙利亚金仓鼠肺部病毒载量，并减轻肺部病变[1]。

[References]

[1]. Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.

[2]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.